THE DEMETHYLENATION OF METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY) BY DEBRISOQUINE HYDROXYLASE (CYP2D6)

Citation
Gt. Tucker et al., THE DEMETHYLENATION OF METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY) BY DEBRISOQUINE HYDROXYLASE (CYP2D6), Biochemical pharmacology, 47(7), 1994, pp. 1151-1156
Citations number
31
Categorie Soggetti
Pharmacology & Pharmacy",Biology
Journal title
ISSN journal
00062952
Volume
47
Issue
7
Year of publication
1994
Pages
1151 - 1156
Database
ISI
SICI code
0006-2952(1994)47:7<1151:TDOM(B>2.0.ZU;2-E
Abstract
The metabolism of methylenedioxymethamphetamine (MDMA, ''ecstasy'') wa s examined in a microsomal preparation of the yeast Saccharomyces cere visiae expressing human debrisoquine hydroxylase, CYP2D6. Only one pro duct, dihydroxymethylamphetamine (DHMA), was detected in the incubatio n mixture, and this product accounted for all of the substrate consump tion at low concentration (10 mu M). Mean +/- SD values of apparent K- m(mu M) and V-max (nmol/min per nmol P450) for the demethylenation of (+) and (-)-MDMA at low concentrations (1-1000 mu M) were 1.72, 0.12 a nd 6.45, 0.10 and 2.90, 0.10 and 7.61, 0.06, respectively. At high con centrations (>1000 mu M) substrate inhibition was noted, with K-i valu es of 14.2 and 28.2 mM, respectively, for the (+) and (-) enantiomers. Incubation of MDMA isomers with human liver microsomes indicated that their demethylenation is deficient in the poor metabolizer phenotype. Thus, MDMA is converted to the catecholamine DHMA by CYP2D6, and this may give rise to genetically-determined differences in toxicity.